Emily Field is ranked #370 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

BARC

Emily Field

Q: How accurate are Emily Field's stock ratings?

About 59% of Emily's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, measured by 13Foresight from historical prices.

Barclays

Wall Street Analyst

★★★★☆

#370

on 13Foresight · ranked by our own returns

59%

Success Rate

+2.6%

Average Return

54 of 91 calls profitable · -78.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 59% of Emily Field's ratings turned a profit when each position was held for 1 year — averaging +2.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Emily's Stock Coverage 28 ratings · 2026-11-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
BMY Bristol-Myers Squibb	Oct 29, 2026	BUY	Buy -2.2% avg upside 42 analysts	$75.00 20.12% Upside	+1.4%	·
LLY Eli Lilly & Co	Oct 29, 2026	BUY	Strong Buy -16.7% avg upside 50 analysts	$1400.00 1.32% Downside	+3.9%	·
MRK Merck & Company	Oct 28, 2026	BUY	Strong Buy -3.5% avg upside 44 analysts	$180.00 20.36% Upside	+4.3%	·
GILD Gilead Sciences	Oct 28, 2026	HOLD	Strong Buy -27.3% avg upside 66 analysts	$145.00 15.10% Downside	+5.6%	·
BIIB Biogen	Oct 28, 2026	HOLD	Strong Buy +6.6% avg upside 53 analysts	$230.00 9.22% Downside	+3.8%	·
AMGN Amgen	Oct 26, 2026	HOLD	Buy -29.9% avg upside 57 analysts	$400.00 14.17% Downside	+5.0%	·
ABBV AbbVie	Oct 21, 2026	BUY	Strong Buy -14.5% avg upside 47 analysts	$325.00 10.12% Upside	+3.6%	·
CYTK Cytokinetics	Aug 26, 2026	BUY	Strong Buy +43.4% avg upside 36 analysts	$110.00 74.61% Upside	-29.1%	·
PFE Pfizer	Aug 13, 2026	SELL	Buy +9.2% avg upside 46 analysts	$25.00 18.15% Downside	-11.1%	·
NVS Novartis	Jan 06, 2026	HOLD	Hold -16.1% avg upside 24 analysts	—	+18.6%	·
SNY Sanofi	Jan 06, 2026	HOLD	Strong Buy +64.5% avg upside 20 analysts	—	+6.1%	·
RHHBY Roche Holding	Jan 06, 2026	BUY	Buy -14.7% avg upside 14 analysts	—	+21.1%	·
GSK GlaxoSmithKline	Jan 06, 2026	SELL	Hold -14.7% avg upside 20 analysts	—	-3.1%	·
CH:ROP Roche Holding AG	Sep 24, 2025	HOLD	Buy -12.1% avg upside 24 analysts	$275.00 31.73% Downside	+45.6%	·
GB:GSK GlaxoSmithKline	Aug 12, 2025	HOLD	Hold +5.2% avg upside 26 analysts	$1450.00 21.84% Downside	+29.4%	·
FR:SAN Sanofi	Aug 12, 2025	BUY	Strong Buy +21.3% avg upside 30 analysts	$105.00 31.69% Upside	-3.0%	·
CH:SDZ Sandoz Group Ltd	Aug 08, 2025	BUY	Buy -14.9% avg upside 12 analysts	$55.00 33.21% Downside	+56.6%	·
GB:AZN AstraZeneca	Jul 30, 2025	BUY	Strong Buy +7.8% avg upside 28 analysts	$14000.00 0.27% Upside	+11.6%	·
NL:LKFT Lakefront Biotherapeutics NV	Jul 29, 2025	SELL	Sell +75.8% avg upside 17 analysts	$22.00 24.00% Downside	+16.7%	·
CH:NOVN Novartis AG	Jul 21, 2025	SELL	Hold -15.0% avg upside 32 analysts	$90.00 32.66% Downside	-40.2%	·
DE:BAYN Bayer	Jun 27, 2025	HOLD	Buy +8.7% avg upside 31 analysts	$25.00 50.65% Downside	+84.6%	·
GB:HIK Hikma Pharmaceuticals	Apr 25, 2025	HOLD	Strong Buy +38.9% avg upside 9 analysts	$2000.00 15.52% Upside	-28.5%	·
DE:MRK Merck KGaA	Oct 29, 2024	BUY	Buy -7.2% avg upside 34 analysts	$195.00 28.86% Upside	-24.2%	·
ES:GRF Grifols	Nov 21, 2022	SELL	Buy +32.5% avg upside 13 analysts	$9.00 17.99% Downside	-25.4%	·
FR:IPN Ipsen	Nov 25, 2021	SELL	Hold -20.5% avg upside 17 analysts	$75.00 52.45% Downside	-25.1%	·
LKFT Lakefront Biotherapeutics	Jan 19, 2021	HOLD	Buy +217.3% avg upside 25 analysts	$125.00 287.24% Upside	-49.2%	·
HK:0013 HUTCHMED (China)	Aug 28, 2020	HOLD	Buy +469.3% avg upside 6 analysts	$52.34 151.80% Upside	·	·
GRFS Grifols SA	Jun 01, 2018	BUY	Buy +179.5% avg upside 13 analysts	—	-19.0%	·

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Emily Field — Frequently Asked Questions

How accurate are Emily Field's stock ratings?

Based on the calls 13Foresight could measure, about 59% of Emily's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, or -78.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Emily ranked on 13Foresight?

Emily Field is currently ranked #370 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Emily cover?

Emily most recently has ratings on BMY, LLY, MRK, GILD, BIIB, AMGN, ABBV, CYTK, PFE, NVS, SNY, RHHBY and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Emily Field

Welcome to 13Foresight!